New drug duo aims to tackle stubborn heart risk factor

NCT ID NCT07614984

Recruiting now Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 8 times

Summary

This Phase 2 trial tests an experimental drug called MK-7262, alone or with another drug called enlicitide, in 750 adults with high levels of lipoprotein(a) – a genetic risk factor for heart disease. The study compares these drugs to a placebo to see if they can safely lower both Lp(a) and LDL cholesterol over 8 weeks. Participants must already be on a stable statin dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MK-7262 (also known as HRS-5346) and enlicitide decanoate (also known as MK-0616)
What this could lead to: If successful, this could lead to a new treatment option for people with high lipoprotein(a), a genetic risk factor for heart disease, by lowering both Lp(a) and LDL cholesterol.
What could go wrong: This is an early Phase 2 trial, so it's not yet proven to work or be safe. The results may not apply to everyone, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIPOPROTEIN(A)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

AMR Clinical Mobile ( Site 0149)
RECRUITING

Mobile, Alabama, 36608, United States
Advanced Cardiovascular - Alexander City ( Site 0158)
RECRUITING

Alexander City, Alabama, 35010, United States
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division ( Site 0132)
RECRUITING

Troy, Michigan, 48098, United States
Carient Heart & Vascular - Manassas ( Site 0165)
RECRUITING

Manassas, Virginia, 20109, United States
Chase Medical Research, LLC ( Site 0163)
RECRUITING

Waterbury, Connecticut, 06708, United States
Clinical Research Trials of Florida ( Site 0101)
RECRUITING

Tampa, Florida, 33607, United States
Conquest Research LLC ( Site 0140)
RECRUITING

Winter Park, Florida, 32789, United States
DM Clinical Research ( Site 0115)
RECRUITING

Tomball, Texas, 77375, United States
Flourish Research - Bowie ( Site 0106)
RECRUITING

Bowie, Maryland, 20715, United States
Headlands Research CTR Lincoln ( Site 0127)
RECRUITING

Lincoln, California, 95648, United States
Holston Medical Group ( Site 0117)
RECRUITING

Kingsport, Tennessee, 37660, United States
Inpatient Research Clinic ( Site 0110)
RECRUITING

Miami Lakes, Florida, 33014, United States
Laurelton Heart Specialist PC ( Site 0155)
RECRUITING

Rosedale, New York, 11422, United States
Montana Medical Research, Inc. ( Site 0156)
RECRUITING

Missoula, Montana, 59808, United States
National Heart Institute ( Site 0113)
RECRUITING

Beverly Hills, California, 90211-2285, United States
New Mexico Clinical Research & Osteoporosis Center ( Site 0119)
RECRUITING

Albuquerque, New Mexico, 87106, United States
Rainier Clinical Research Center ( Site 0116)
RECRUITING

Renton, Washington, 98057, United States
Remington-Davis, Inc. ( Site 0107)
RECRUITING

Columbus, Ohio, 43215, United States
Soffer Health Institute ( Site 0123)
RECRUITING

Hollywood, Florida, 33020, United States
Velocity Clinical Research Rockville ( Site 0146)
RECRUITING

Rockville, Maryland, 20854, United States
Velocity Clinical Research, Durham ( Site 0145)
RECRUITING

Durham, North Carolina, 27701, United States
Westside Center for Clinical Research ( Site 0161)
RECRUITING

Jacksonville, Florida, 32205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.